Amgen, Inc. recalls MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Ma
Recalled May 18, 2022 · FDA recall D-0855-2022 · Amgen
Hazard
Defective container: loose crimp defect, potential loss of container integrity. · FDA Class II
Units
15,823
Sold at
Nationwide in the USA, Egypt and Lithuania.
Description
Defective container: loose crimp defect, potential loss of container integrity.
Product
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
Manufacturer(s)
Amgen, Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →